Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma

Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems. A phase I study was conducted to determine the maximum tolerated dose (MTD) of sorafenib in patients with recurrent malignant glioma. S...

Full description

Saved in:
Bibliographic Details
Main Authors: Nabors, L. B., Supko, J. G., Rosenfeld, M., Chamberlain, M., Phuphanich, S., Batchelor, T., Desideri, S., Ye, X., Wright, J., Gujar, S., Grossman, S. A.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2011
Subjects:
Clinical Investigations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223097/
https://ncbi.nlm.nih.gov/pubmed/21954442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor145
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items